BIOMAT Database Logo BIOMAT Database Logo

Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. 1995

T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
Clinical Studies Branch, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702-5011, USA.

New vaccines are needed to prevent cholera caused by Vibrio cholerae O139. Attenuated V cholerae O139 vaccines were made by deleting multiple copies of the cholera-toxin genetic element from two virulent strains of the organism, MO10 and AI4456. The deletion mutants were further modified by insertion of a construct that encoded the B subunit of cholera toxin, thus generating strains Bengal-3 and VRI-16. A stable spontaneous non-motile derivative of Bengal-3 was isolated and designated Bengal-15; VRI-16 is naturally non-motile. Bengal-3, Bengal-15, and VRI-16 were evaluated as oral single-dose cholera vaccine candidates in 4 volunteers each, and MO10 was given to 3 volunteers. 1 of 4 volunteers who received Bengal-3 and all 3 who received MO10 had diarrhoea. VRI-16 caused no significant symptoms but was not immunogenic. Bengal-15 produced few symptoms and was nearly as immunogenic as MO10. Subsequently, Bengal-15 was given to 10 volunteers at a dose of 10(8) colony-forming units. No volunteers had diarrhoea, and other subjective symptoms were as common in vaccinees as in 3 buffer recipients. 1 month after vaccination, 7 vaccinees, the 3 buffer recipients, and 3 unimmunised subjects were challenged with 5 x 10(6) colony-forming units of V cholerae O139. 5 of 6 controls had cholera-like diarrhoea. By contrast, 1 of 7 vaccinees had diarrhoea, which was mild and had a long incubation period. Vaccine protective efficacy was 83%. Our results indicate the Bengal-15 is a safe live attenuated vaccine candidate for cholera caused by the O139 serogroup.

UI MeSH Term Description Entries
D002771 Cholera An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated. Vibrio cholerae Infection,Choleras,Infection, Vibrio cholerae,Infections, Vibrio cholerae,Vibrio cholerae Infections
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated
D014734 Vibrio cholerae The etiologic agent of CHOLERA. Bacillus cholerae,Bacillus cholerae-asiaticae,Liquidivibrio cholerae,Microspira comma,Pacinia cholerae-asiaticae,Spirillum cholerae,Spirillum cholerae-asiaticae,Vibrio albensis,Vibrio cholera,Vibrio cholerae-asiaticae,Vibrio comma
D022121 Cholera Vaccines Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist. Cholera Vaccine,Vaccine, Cholera,Vaccines, Cholera

Related Publications

T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects.
January 1995, Developments in biological standardization,
T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge.
September 1995, The Journal of infectious diseases,
T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.
December 2004, Expert review of vaccines,
T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine.
October 1995, The Journal of pediatrics,
T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype.
August 1994, The Journal of infectious diseases,
T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.
November 2004, Journal of virology,
T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
Construction and characterization of a potential live oral carrier-based vaccine against Vibrio cholerae O139.
September 1996, Infection and immunity,
T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
Safety and immunogenicity of live attenuated rhesus monkey rotavirus vaccine.
December 1986, The Journal of infectious diseases,
T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
[Safety and immunogenicity of lyophilized live attenuated domestic varicella vaccine].
October 2009, Zhongguo yi miao he mian yi,
T S Coster, and K P Killeen, and M K Waldor, and D T Beattie, and D R Spriggs, and J R Kenner, and A Trofa, and J C Sadoff, and J J Mekalanos, and D N Taylor
Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm.
January 1999, Current topics in microbiology and immunology,
Copied contents to your clipboard!